Research & drug development news: European Public Health Alliance joins Europe-wide challenge to patent for Hepatitis C treatment
An announcement today in Europe (press release below) brings a new angle to the copious US coverage of drug pricing, such as predatory pricing of the EpiPen and the smirking, seemingly sociopathic Martin Shkreli. For the drug described below, the Médecins du Monde (Doctors of the World, below) blog says, “While [this drug is] a major therapeutic advance, the molecule itself, which is the result of work by many public and private researchers, is not sufficiently innovative to warrant a patent.”
That touches on another hot topic in the US: the use and re-use of data from government-funded research – whose data is it? Who owns the intellectual property? That’s what Vice President Biden spoke about (my video) at Health Datapalooza last year, and it’s at the core of the New England Journal’s SPRINT Data Analysis Challenge, which we blogged about last fall – its winners have been announced and there will be a free live two-day web event April 3-4 in Boston. That challenge arose out of a controversial editorial that said some people consider data sharing to be a “parasite” problem.
Whose data is it? Whose IP is it? What are the rights of investors vs the people who have the problem, aka “patients”?
Brussels, 27 March 2017